GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-07-29| COVID-19Partnerships

Moderna to Supply 66 Million COVID-19 Boosters to US

by Max Heirich
Share To

On July 29, Moderna announced they would supply the U.S. government with 66 million doses of their COVID-19 vaccine booster. This booster contains both Spikevax as well as Omicron mRNA strain. In return, Moderna will receive up to $1.74 billion for manufacturing and delivering the doses. 

Related Article: NIH Launches mRNA Nipah Virus Vaccine Trial With Moderna

The Bivalent Vaccine Protects Against Multiple Strains

These new COVID-19 boosters supplied to the U.S. government contain Spikevax, the brand name for Moderna’s mRNA COVID-19 vaccine. The boosters are functionally equivalent to the two-dose primary series of vaccines that a patient initially receives. The third booster bolsters a body’s immune response to COVID-19 after the initial protection begins to wear off.

In addition, the vaccines ordered today contain a strain of mRNA to protect against the Omicron BA.4/5 strain of COVID-19. This bivalent vaccine, dubbed mRNA-1273.222, is a vaccine that protects against two different antigens. Moderna developed it in accordance with recent FDA recommendations.

66 million Vaccine Boosters for $1.74 billion

Not only does the finalized contract secure 66 million doses of the bivalent COVID-19 vaccine, but it leaves room for the additional purchasing of up to 234 million doses from Moderna. The U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA) supported the funds for the contract.

Stéphane Bancel, Chief Executive Officer of Moderna, said in a statement, “We are pleased to extend our successful collaboration with the U.S. government. Moderna’s mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets Omicron subvariants BA.4 and BA.5, the most prevalent variants of concern in the U.S. today. We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against COVID-19.”

This deal indicates the ongoing effort by Moderna and other biotech companies to innovate and adapt to the various COVID-19 variants born of the ongoing pandemic.

Related Article: EMA Begins Reviewing Cancer Medicine for COVID-19 Without Manufacturer’s Application

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
Rising Bird Flu Cases in Cattle and Humans Drive Global Efforts in Vaccination, Genetic Monitoring, and Surveillance
2024-07-17
Moderna and Mitsubishi Tanabe Pharma Partner on mRNA Respiratory Vaccines in Japan
2024-07-11
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top